乳腺癌淋巴引流区放疗后手臂与肩部晚期正常组织效应:英国START试验结果
该分析基于START pilot、A和B三项随机试验,评估早期乳腺癌患者接受淋巴引流区放疗(LNRT)后手臂与肩部晚期不良反应。864/5861(14.7%)患者接受LNRT,中重度手臂/肩部效应10年内发生率低;START-A和B中大分割与常规分割组患者及医生评估症状无显著差异,START-pilot中13次3.3 Gy方案不良反应率较高。
要点
- LNRT后中重度手臂/肩部效应10年内发生率低。
- START-A和B中大分割与常规分割组手臂/肩部症状无显著差异。
- START-pilot中13次3.3 Gy方案肩部僵硬风险显著升高(HR 3.07)。
核心结论
- START试验结果提示,适当剂量的大分割LNRT长期手臂与肩部症状安全。
- 该结果与相同方案照射乳腺/胸壁后报告的结果一致。
研究设计与样本
- START pilot、A和B三项随机试验将早期乳腺癌女性随机分配至2.67-3.3 Gy/次 versus 2.0 Gy/次(对照)方案。
- 864/5861(14.7%)患者接受LNRT(START-pilot 385例,START-A 318例,START-B 161例)。
- 放疗不良反应由患者使用EORTC QLQ-BR23及方案特定问题评估,并由医生评估。
主要发现
- LNRT患者中重度手臂/肩部效应10年内发生率低。
- START-A或START-B中大分割组与对照组患者及医生评估症状无显著差异。
- START-pilot中13次3.3 Gy方案后不良反应率较高,肩部僵硬显著(HR 3.07,95%CI 1.62-5.83,p=0.001)。
临床怎么用
- 对适合的腋窝淋巴结阳性早期乳腺癌患者,可考虑适当剂量的大分割LNRT。
- 应避免START-pilot中13次3.3 Gy方案以降低肩部僵硬风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with similarly-hypofractionated breast/chest wall radiotherapy (RT). MATERIAL AND METHODS: The Standardisation of Breast Radiotherapy (START) pilot, A and B trials randomised women with early breast cancer to schedules of 2.67-3.3 Gy versus 2.0 Gy fractions (control). RT adverse effects were assessed by patients using the EORTC QLQ-BR23 and protocol-specific questions, and by physicians. Rates of arm/shoulder effects were compared between schedules for patients given LNRT. RESULTS: 864/5861 (14.7%) patients received LNRT (385 START-pilot, 318 START-A, 161 START-B). Prevalences of moderate/marked arm/shoulder effects were low up to 10 years. There were no significant differences between the hypofractionated and control groups for patient- and physician-assessed symptoms in START-A or START-B. In START-pilot, adverse effect rates were higher after 13 fractions of 3.3 Gy, consistent with effects reported in the breast/chest wall (significant for shoulder stiffness, HR 3.07, 95%CI 1.62-5.83, p = 0.001). CONCLUSIONS: The START trial results suggest that appropriately-dosed hypofractionated LNRT is safe in the long-term, according to patient and physician-assessed arm and shoulder symptoms. These findings are consistent with those reported after the same schedules delivered to the breast/chest wall.
引用
- Haviland JS, Mannino M, Griffin C, et al. Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol. 2017. PMID: 29153463. doi:10.1016/j.radonc.2017.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。